First Affirmative Financial Network Sells 49 Shares of IQVIA Holdings Inc. (NYSE:IQV)

First Affirmative Financial Network trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,105 shares of the medical research company’s stock after selling 49 shares during the quarter. First Affirmative Financial Network’s holdings in IQVIA were worth $279,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of IQV. Norges Bank bought a new position in IQVIA during the 4th quarter worth approximately $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of IQVIA by 339.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after buying an additional 1,597,003 shares during the last quarter. Morningstar Investment Services LLC grew its position in shares of IQVIA by 96.9% in the 4th quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock worth $286,704,000 after buying an additional 606,333 shares during the last quarter. Capital Research Global Investors grew its position in shares of IQVIA by 42.2% in the 4th quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after buying an additional 592,372 shares during the last quarter. Finally, Eagle Asset Management Inc. bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $102,982,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on IQV shares. The Goldman Sachs Group started coverage on IQVIA in a research report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective on the stock. Robert W. Baird dropped their price target on IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a research report on Friday, May 3rd. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Truist Financial dropped their price target on IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a research report on Friday, May 3rd. Finally, StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Friday. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $258.40.

IQVIA Stock Up 1.0 %

IQV stock opened at $216.25 on Friday. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The business has a fifty day moving average price of $225.57 and a 200-day moving average price of $230.28. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. The stock has a market capitalization of $39.40 billion, a P/E ratio of 29.54, a P/E/G ratio of 1.95 and a beta of 1.53.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The firm had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. Equities analysts forecast that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.